{
    "clinical_study": {
        "@rank": "46709", 
        "arm_group": [
            {
                "arm_group_label": "Ketamine", 
                "arm_group_type": "Active Comparator", 
                "description": "Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The placebo will consist of 4 ml of cherry syrup and 1 ml of normal saline."
            }
        ], 
        "brief_summary": {
            "textblock": "-  The primary objective is to determine the reduction in pain score by ketamine mouthwash\n           compared to placebo in head and neck cancer patients with refractory mucositis.\n\n        -  The secondary objectives are to describe the duration of analgesia and adverse effects\n           associated with ketamine and placebo."
        }, 
        "brief_title": "Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head and Neck Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Mucositis", 
            "Head and Neck Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Head and Neck Neoplasms", 
                "Mucositis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects diagnosed with head and neck tumors (any histology) receiving ongoing\n             chemoradiation or radiation therapy\n\n          -  Subjects with mucositis pain refractory to topical management, defined as any\n             self-reported pain score of > 2 in the 24 hours prior to enrollment despite use of\n             topical agents as prescribed\n\n          -  Age \u2265 18 years\n\n          -  Ability to understand and willingness to consent and to sign consent form\n\n        Exclusion Criteria:\n\n          -  Active substance abuse at time of registration (alcohol, drugs, non-prescription use\n             of controlled substances)\n\n          -  Subjects with history of allergic reactions to ketamine\n\n          -  Persistent oral bleeding: > 15 mL (estimated) per day\n\n          -  Pregnancy or breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653327", 
            "org_study_id": "D1022"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ketamine", 
                "description": "Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.", 
                "intervention_name": "Ketamine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Analgesics", 
                "Ketamine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "mucositis", 
            "head and neck", 
            "cancer", 
            "radiation therapy", 
            "chemoradiation", 
            "oral", 
            "pain"
        ], 
        "lastchanged_date": "February 14, 2014", 
        "location": {
            "contact": {
                "email": "cancer.research.nurse@dartmouth.edu", 
                "last_name": "Research Nurse", 
                "phone": "800-639-6918"
            }, 
            "facility": {
                "address": {
                    "city": "Lebanon", 
                    "country": "United States", 
                    "state": "New Hampshire", 
                    "zip": "03756"
                }, 
                "name": "Dartmouth-Hitchcock Medical Center"
            }, 
            "investigator": {
                "last_name": "Thomas H Davis, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head and Neck Cancer", 
        "overall_contact": {
            "email": "thomas.h.davis@hitchcock.org", 
            "last_name": "Thomas H Davis, MD", 
            "phone": "603-650-8626"
        }, 
        "overall_official": {
            "affiliation": "Dartmouth-Hitchcock Medical Center", 
            "last_name": "Thomas H David, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Data Safety Monitoring and Accrual Committee", 
                "United States: Federal Government", 
                "United States: Food and Drug Administration", 
                "United States: Committee for the Protection of Human Subjects"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary analysis is testing and estimating the effect of ketamine in comparison to placebo. Pain assessment will be analyzed using descriptive statistics. We will also determine average pain scores and average duration of analgesia. The effect of ketamine in comparison to placebo will be estimated with a mean and confidence interval. Proportional reductions in pain scores (post-treatment pain score \u00f7 pre-treatment pain score) will be calculated and similarly analyzed. The proportion of subjects experiencing a reduction in pain scores of >33% will be calculated.", 
            "measure": "Reduction in Pain Score", 
            "safety_issue": "No", 
            "time_frame": "After 9 doses, expected average 1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653327"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Dartmouth-Hitchcock Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dartmouth-Hitchcock Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}